Last reviewed · How we verify
tirofiban high-bolus dose regimen
Tirofiban, a high-bolus dose regimen developed by the University of Bologna, is currently marketed but lacks detailed revenue figures and primary indication data. A key strength is the patent protection extending to 2028, which secures market exclusivity for the composition. The primary risk lies in the lack of clear competitive positioning and trial results, which may impact market adoption and reimbursement.
At a glance
| Generic name | tirofiban high-bolus dose regimen |
|---|---|
| Also known as | Aggrastat |
| Sponsor | University of Bologna |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI (PHASE4)
- FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tirofiban high-bolus dose regimen CI brief — competitive landscape report
- tirofiban high-bolus dose regimen updates RSS · CI watch RSS
- University of Bologna portfolio CI